$380 Million is the total value of INTERWEST VENTURE MANAGEMENT CO's 12 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 7.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PMVP | Sell | PMV PHARMACEUTICALS INC | $179,905,000 | -54.8% | 5,469,911 | -15.5% | 47.32% | -4.8% |
| AI | Sell | C3.AI | $91,402,000 | -62.0% | 1,386,774 | -20.0% | 24.04% | -20.0% |
| REAL | Sell | THE REALREAL | $53,273,000 | -29.3% | 2,354,080 | -38.9% | 14.01% | +49.0% |
| GKOS | Sell | GLAUKOS CORP | $29,071,000 | -40.2% | 346,364 | -46.4% | 7.65% | +25.9% |
| AGTC | APPLIED GENETIC TECHNOL CORP | $7,121,000 | +24.0% | 1,404,515 | 0.0% | 1.87% | +161.2% | |
| EIGR | EIGER BIOPHARMACEUTICALS INC | $6,770,000 | -28.0% | 764,918 | 0.0% | 1.78% | +51.7% | |
| STIM | Sell | NEURONETICS INC | $6,150,000 | -44.3% | 497,158 | -50.0% | 1.62% | +17.2% |
| CDTX | CIDARA THERAPEUTICS INC | $3,609,000 | +33.0% | 1,356,813 | 0.0% | 0.95% | +179.9% | |
| VERO | VENUS CONCEPT INC | $1,548,000 | +35.9% | 658,657 | 0.0% | 0.41% | +186.6% | |
| OBALON THERAPEUTICS INC | $1,072,000 | +88.1% | 380,224 | 0.0% | 0.28% | +297.2% | ||
| XENE | XENON PHARMACEUTICALS INC | $148,000 | +15.6% | 8,293 | 0.0% | 0.04% | +143.8% | |
| DARE | DARE BIOSCIENCE INC | $85,000 | +26.9% | 50,368 | 0.0% | 0.02% | +175.0% | |
| KALV | Exit | KALVISTA PHARMACEUTICALS INC | $0 | – | -388,766 | -100.0% | -0.92% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-04-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GLAUKOS CORP | 28 | Q3 2023 | 33.0% |
| EIGER BIOPHARMACEUTICALS INC | 24 | Q3 2022 | 17.7% |
| APPLIED GENETIC TECHNOL CORP | 24 | Q3 2022 | 6.7% |
| XENON PHARMACEUTICALS INC | 20 | Q3 2021 | 0.6% |
| CIDARA THERAPEUTICS INC | 19 | Q2 2021 | 4.5% |
| THE REALREAL | 18 | Q3 2023 | 62.6% |
| KALVISTA PHARMACEUTICALS INC | 17 | Q4 2020 | 10.8% |
| DARE BIOSCIENCE INC | 16 | Q3 2023 | 0.3% |
| MACROGENICS INC | 14 | Q1 2020 | 19.2% |
| PMV PHARMACEUTICALS INC | 13 | Q3 2023 | 67.5% |
View INTERWEST VENTURE MANAGEMENT CO's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 144 | 2024-02-27 |
| 13F-HR | 2023-10-20 |
| 13F-HR | 2023-07-21 |
| 13F-HR | 2023-04-27 |
| 13F-HR | 2023-01-31 |
| 13F-HR | 2022-10-25 |
| 13F-HR | 2022-08-02 |
| 13F-HR | 2022-04-13 |
| 13F-HR | 2022-01-25 |
| 13F-HR | 2021-10-19 |
View INTERWEST VENTURE MANAGEMENT CO's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.